HomeCompareRHHBF vs EPRT

RHHBF vs EPRT: Dividend Comparison 2026

RHHBF yields 2.28% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $34.7K in total portfolio value
10 years
RHHBF
RHHBF
● Live price
2.28%
Share price
$410.32
Annual div
$9.37
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.7K
Annual income
$1,518.26
Full RHHBF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — RHHBF vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRHHBFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RHHBF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RHHBF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RHHBF
Annual income on $10K today (after 15% tax)
$194.20/yr
After 10yr DRIP, annual income (after tax)
$1,290.52/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $9,624.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RHHBF + EPRT for your $10,000?

RHHBF: 50%EPRT: 50%
100% EPRT50/50100% RHHBF
Portfolio after 10yr
$46.0K
Annual income
$7,179.49/yr
Blended yield
15.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

RHHBF
Analyst Ratings
3
Buy
5
Hold
1
Sell
Consensus: Hold
Altman Z
5.3
Piotroski
6/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RHHBF buys
0
EPRT buys
0
No recent congressional trades found for RHHBF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRHHBFEPRT
Forward yield2.28%3.92%
Annual dividend / share$9.37$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17%29%
Portfolio after 10y$28.7K$63.4K
Annual income after 10y$1,518.26$12,840.73
Total dividends collected$7.3K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: RHHBF vs EPRT ($10,000, DRIP)

YearRHHBF PortfolioRHHBF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,967$267.32$11,205$505.18$238.00EPRT
2$12,056$320.57$12,672$682.46$616.00EPRT
3$13,285$385.32$14,490$930.48$1.2KEPRT
4$14,679$464.29$16,786$1,282.69$2.1KEPRT
5$16,268$560.96$19,753$1,791.56$3.5KEPRT
6$18,086$679.77$23,677$2,541.64$5.6KEPRT
7$20,178$826.39$29,008$3,672.99$8.8KEPRT
8$22,599$1,008.16$36,463$5,425.08$13.9KEPRT
9$25,416$1,234.62$47,238$8,221.57$21.8KEPRT
10$28,713$1,518.26$63,385$12,840.73$34.7KEPRT

RHHBF vs EPRT: Complete Analysis 2026

RHHBFStock

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.

Full RHHBF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this RHHBF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RHHBF vs SCHDRHHBF vs JEPIRHHBF vs ORHHBF vs KORHHBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.